<DOC>
	<DOCNO>NCT02976766</DOCNO>
	<brief_summary>The purpose study determine whether gypenosides neuroprotective patient acute optic neuritis .</brief_summary>
	<brief_title>Gypenosides Treatment Optic Neuritis</brief_title>
	<detailed_description />
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<criteria>Inclusion criterion 1 . Male female Chinese patient age ≥18 ≤60 year 2 . Patients first episode unilateral bilateral optic neuritis 3 . First symptoms optic neuritis ≤28 day prior first administration investigational product 4 . Best correct visual acuity bad eye ≤0.8 Exclusion criteria 1 . Preexisting multiple sclerosis MS NMO 2 . Refractive medium opacity 3 . Hyperopia &gt; 5 diopter , myopia &lt; 5 diopter , astigmatism &gt; 3 diopter 4 . Active tuberculosis , hepatitis , renal insufficiency , uncontrolled hypertension , diabetes mellitus , infection HIV syphilis , condition potentially interfere treatment trial 5 . Other autoimmune disease ( systemic lupus erythematosus , rheumatoid arthritis , etc ) 6 . Existing retina optic nerve diseases 7 . Pregnant female plan pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neuroprotection</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Traditional Chinese medicine</keyword>
	<keyword>Axonal loss</keyword>
	<keyword>Jiaogulan</keyword>
	<keyword>Gynostemma pentaphyllum</keyword>
	<keyword>Optical coherence tomography</keyword>
</DOC>